Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge

Precision Therapeutics (NASDAQ:AIPT) formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis has secured a license agreement with CellBridge Incorporated which grants it access to CellBridge’s 3D biomimetic support technology. This follows the Company’s recently announced license agreements with SyntArray and 48Hour Discovery and is the latest milestone in the Company’s strategy to bring together ground-breaking technologies to develop the next generation of patient derived tumor models for precision cancer therapy and drug development.

As quoted in the press release:

TumorGenesis is developing a new approach to growing tumor models in the laboratory that is faster, less costly and more closely mimics the characteristics of the patient’s tumor, than the traditional PDx animal models that are currently on the market. TumorGenesis’ innovative approach is comprised of three key steps: first, the tumor cells from the patient tumor biopsy are tagged using peptides targeted to the patient’s specific cancer cells; second, the tags adhere the cells to a 3D biomimetic support in the well of a standard 96 well microplate; and third, the tumor cells are grown in the 3D culture system until ready for testing.

Click here to read the full press release.